42
total announcements
EMCURE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹35,404 Cr
P/E (TTM)
35.0
P/E (Forward)
24.0
EPS (TTM)
₹53.35
52W Low
₹1,306.50
52W High
₹2,100.70
Dividend Yield
0.19%
Beta
-0.08
Price / Book
7.1
Debt / Equity
30.6
Revenue (TTM)
₹9,683 Cr
Gross Margin
59.43%
Operating Margin
15.44%
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about the schedule of an earnings call to discuss the company's unaudited financial results for the quarter and half-year ended September 30, 2026.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no securities were received for dematerialization during the quarter ended September 30, 2026.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has approved the proposed Scheme of Amalgamation of its wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, with the company, subject to regulatory approvals.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about the pendency of litigation(s)/dispute(s) or the outcome impacting the Company. The Company has received various orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Year 2014-15 to Financial Year 2020-21.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation, which includes a detailed overview of the company's business strategy, expansion plans, R&D pipeline, and financial performance. The presentation highlights the company's diversified pharmaceutical business with scale in India and differentiated international businesses.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company, following the 45th Annual General Meeting (AGM) held on September 21, 2026. The AGM approved the retirement of Mr. Berjis Desai, re-appointment of Dr. Mukund Gurjar and Mr. Satish Mehta, and appointment of Mr. Raghu Kumar as Independent Director.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 21, 2026, and informed the Exchange regarding voting results.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 21, 2026. The meeting was conducted through Video Conferencing and the proceedings have been uploaded on the company's website.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange regarding the allotment of 11,400 shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013. The issued and paid-up share capital of the Company has increased to 18,97,10,647 Equity Shares of Rs. 10/- each, aggregating to Rs. 1,89,71,06,470/-.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has dispatched a letter to unregistered members providing a web-link to the Annual Report 2025-26 and Notice of 45th Annual General Meeting. The meeting is scheduled for September 21, 2026, through Video Conferencing. Members are also requested to update their KYC details and dematerialize physical securities.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about the proposed schedule of participation in Investor Meet by Officials of the Company.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has announced that CARE Ratings Limited has reaffirmed its credit ratings on the company's bank facilities, citing a healthy business risk profile, diversified revenue base, and strong management team.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has published a newspaper advertisement for its 45th Annual General Meeting (AGM) to be held on September 21, 2026, through video conferencing. The company has also provided details of remote e-voting facility for its members to cast their votes on the resolutions proposed to be passed at the AGM.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange regarding the allotment of 19,100 shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has announced the transcript of its Q1 FY27 earnings call, where the company's management discussed its financial results, organizational updates, and future plans. The company's Chairman, Berjis Desai, is stepping down from the Board of Directors due to his appointment as a member of the National Commission for Minorities, and Satish Mehta will take on the role of Chairman in addition to his existing role as Managing Director and CEO. Samit Mehta has also taken over as Chief Operating Officer.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the USFDA, with the inspection status of the formulations facility at Sanand, Ahmedabad, classified as Voluntary Action Indicated (VAI) and closed.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about the schedule of meet for Analyst/ Investor Meeting(s) to be held on various dates.
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has informed the Exchange about the proposed schedule of participation in Investor Conferences by Officials of the Company.